CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

Maxime MelocheMichael KhazakaImad KassemAmina BarhdadiMarie-Pierre DubéSimon de Denus

Published in: British journal of clinical pharmacology (2020)

Patients without any CYP2D6 metabolic capacities appear to have increased reduction in DBP, HR and SBP during metoprolol treatment and may be at a higher risk of bradycardia compared to patients with active CYP2D6 phenotypes. Further prospective data are required to determine whether CYP2D6 is associated with clinical events in patients treated with metoprolol, as well as to demonstrate the clinical utility of an individualized approach of prescribing metoprolol using CYP2D6-inferred phenotypes.

Keyphrases

end stage renal disease
primary care
ejection fraction
chronic kidney disease
emergency department
machine learning
big data
combination therapy
adverse drug